Diabetes Research and Clinical Practice · Nov 13, 2026
Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis
By Li S, Li S, Xu P et al.
Whether tirzepatide’s kidney effects extend from albuminuria lowering to filtration preservation and clinical outcomes remains uncertain. We searched PubMed, Embase, and the Cochrane Library through August 2026 and mapped randomized reports to independent parent trials. Ten parent trials provided kidney data; eight informed each principal synthesis. Versus insulin, tirzepatide reduced urinary albumin-to-creatinine ratio by 27.0% (95% CI, 16.0%–36.6%; I2 = 37.8%; moderate certainty), whereas placebo-controlled evidence was uncertain (−18.1%; 95% CI, −43.2% to 18.3%; very low certainty). Fixed-time creatinine-based estimated glomerular filtration rate showed no clear benefit (0.36 mL/min/1.73 m2; 95% CI, −0.34 to 1.07; low certainty). In SURPASS-CVOT, approximate post hoc aggregate contrasts suggested larger high-risk effects for filtration and a hard-only composite, but were multiplicity-unadjusted and not formal individual-participant interaction tests. In that high-risk stratum, the hard-only hazard ratio versus dulaglutide was 0.70 (0.57–0.86), while end-stage kidney disease was not clearly reduced (1.04; 0.70–1.55). Albuminuria lowering versus insulin was reproducible; hard-outcome benefit was population- and endpoint-dependent, and dedicated kidney-outcome trials remain needed.
doi.org/10.1016/j.diabres.2026.113668PubMed 43025465Interventions